Follow on your favorite platform
Several times a month, a South Asian woman sits across from me with labs that don't match her reflection: blood sugar creeping up, triglycerides high, HDL low. She is, by every chart in the room, "slim."
Often somebody has already told her the strangest sentence in medicine:
"But you're so thin."
This week on Endocrine Matters, I talk about why that happens, and about something genuinely new: GLP-1 medications you can take as a once-a-day pill, at cash prices that start around $150 a month. Watch the full episode on my channel.
Thin On The Outside, Metabolic On The Inside
South Asians tend to develop metabolic disease at lower body weights than many other groups. We carry more fat on the inside (around the belly, around the organs, in the liver) even when the number on the scale looks completely normal.
Our insulin-making beta cells tend to tire earlier, so insulin resistance, prediabetes, and type 2 diabetes arrive younger and at lower weights, and heart risk starts earlier too.
It's why health organizations recommend lower BMI thresholds for South Asians, and why so many of us are told "you're fine" when we're not quite fine.
There's a clinical name for this pattern, "metabolically obese, normal weight," but the plain version is the one that sticks: thin on the outside, metabolic on the inside.
The New Pills: The Wegovy Pill And Foundayo
Most people know the weekly GLP-1 injections: Ozempic, Wegovy, Mounjaro, Zepbound. What's new is the pill form.
The Wegovy pill is an oral version of semaglutide. Foundayo (orforglipron) is a newer once-a-day pill that doesn't need to be timed around food and water.
In trials, the pills tend to produce somewhat less weight loss than the most powerful injectables, especially at lower doses. That sounds like a downside until you remember the woman at the top of this post.
She doesn't need to lose 20 percent of her body weight. She needs better insulin sensitivity, lower triglycerides, less fat around her organs, and lower heart risk.
An Honest Hypothesis (And The Honest Fine Print)
Here is my thinking, clearly labeled: it is a hypothesis, not proven science.
Lower-dose oral GLP-1s might be a happy middle ground for South Asians with metabolic disease who don't have obesity, improving metabolic markers with less weight loss than the injectables, which is exactly what the thin-outside, metabolic-inside body needs.
There's reason for optimism: in the orforglipron trial program, the drug improved waist circumference, non-HDL cholesterol, triglycerides, and blood pressure, and those trials included participants from Asian countries, including India.
Now the fine print, which matters just as much. These medications are approved for people with obesity, or who are overweight with a weight-related condition. For a normal-weight person, use would generally be off-label: a careful, individualized decision with a doctor who knows you and knows these medications well.
And there is no good data yet specifically on normal-weight South Asians with metabolic syndrome. That study hasn't been done. We deserve data that looks like us, and I hope researchers are listening.
The Price Piece: Access, Finally
The injectables have been expensive. Even after price cuts, cash prices have run in the hundreds of dollars a month.
The oral versions start much lower: cash pricing for the two lowest doses starts around $150 a month.
For a community where many of us don't qualify for insurance coverage because our BMI isn't "high enough," that difference can be the line between "this isn't for people like me" and "this is actually possible."
The Menopause Connection
When estrogen drops in perimenopause and menopause, metabolism shifts: more belly fat, more insulin resistance, changed cholesterol. For South Asian women, who often start with more of both, midlife can feel like pouring gasoline on a fire.
There is early, encouraging, observational data that women on menopausal hormone therapy while taking a GLP-1 lost more weight than women who weren't. Not the final word, but a signal that estrogen and GLP-1s may work well together.
For the right South Asian woman in midlife, with the right doctor, treating the hormonal piece and the metabolic piece together, instead of pretending they're separate, may be a powerful combination.
Why This Isn't A Seven-Minute Conversation
Everything above (off-label considerations, lower BMI thresholds, hormones plus GLP-1s, lab trends over time) takes time, expertise, and a doctor who knows our community.
In the traditional system, too many of us fall through the cracks: BMI not "high enough" for coverage, labs "borderline, watch it, come back in a year," three to six months to see an endocrinologist for 15 minutes.
That's why I practice direct care: transparent monthly pricing, real access, longer visits, labs at cash prices that are a fraction of the usual, and a doctor who can follow you closely if you start something new.
The Bottom Line
You can be thin on the outside and metabolic on the inside. A normal BMI does not mean a normal metabolism for South Asians. The new oral GLP-1s are promising and newly affordable, the data for our community is still coming, and the right next step is the oldest one in medicine: ask for the labs, ask about your waist, and find a doctor who sees the whole picture.
If you want that doctor, one who knows what's actually in your dal and your roti and won't just tell you to "eat a salad," that's what Complete Medicine was built for. Learn more here.
๐ Still have questions?
๐ฌ Contact us and we'll be happy to help!
๐ Or join our newsletter to stay informed: Sign up here
FAQs
What is Foundayo (orforglipron)? A newly FDA-approved oral GLP-1 medication: a once-a-day pill that doesn't need to be taken on an empty stomach or timed around food and water. In trials it improved weight, waist circumference, non-HDL cholesterol, triglycerides, and blood pressure.
How much does the Wegovy pill cost? Cash pricing for the lowest oral GLP-1 doses starts around $150 a month, substantially below typical cash prices for the injectables.
Can you take a GLP-1 if you're not overweight? Current approvals cover obesity, or overweight with a weight-related condition. For a normal-weight person, use would generally be off-label: a careful, individualized decision with a doctor who knows you and these medications well. There is not yet good trial data on normal-weight South Asians with metabolic syndrome.
Why do South Asians get diabetes at normal weights? We tend to carry more fat internally (around organs and in the liver), and our beta cells tire earlier, so insulin resistance and type 2 diabetes develop younger and at lower weights, which standard BMI cutoffs miss.
Can you take hormone therapy and a GLP-1 together? Early observational studies suggest women on menopausal hormone therapy while taking a GLP-1 lost more weight than women who weren't. It's not definitive, but it supports having the hormonal and metabolic conversation together with a menopause-trained clinician.
What labs should I ask for if I'm "thin but worried"? A1c or fasting glucose, triglycerides, HDL, and blood pressure, and ask about your waist measurement, not just your weight.